Merck & Co., Inc. (MRK)
NYSE · Healthcare · Drug Manufacturers - General
$139.54−3.30%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $344B
- P/E (trailing)
- 110.8
- Forward P/E
- 14.7
- Dividend yield
- 2.4%
- 52-week range
- $82.01 – $156.92
- 52-week change
- +64.71%
- EPS (trailing)
- $1.26
- Analyst rating
- 1.8 Buy
- Next earnings
- Oct 29, 2026
Fiscal year to Dec 2025
- Revenue
- $65.0B (+1.31%)
- Net income
- $18.3B
- Diluted EPS
- $7.28
- Free cash flow
- $12.4B
From the company’s annual report on SEC EDGAR.
About Merck & Co., Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare,…
Headquarters: Rahway, United States · 73,000 employees · merck.com